EMEA-002211-PIP01-17
Key facts
| Active substance |
Resminostat
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0376/2017
|
| PIP number |
EMEA-002211-PIP01-17
|
| Pharmaceutical form(s) |
Coated tablet
|
| Condition(s) / indication(s) |
Treatment of Cutaneous T-Cell Lymphoma
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
4SC AG
Tel. +49 897007630
E-mail: public@4sc.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|